UK markets closed

Salarius Pharmaceuticals, Inc. (SLRX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5045+0.0076 (+1.53%)
As of 12:00PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 2.09M
Enterprise value -3.52M
Trailing P/E 1.80
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.40
Enterprise value/revenue N/A
Enterprise value/EBITDA 0.27

Trading information

Stock price history

Beta (5Y monthly) 1.00
52-week change 3-71.64%
S&P500 52-week change 321.23%
52-week high 32.3100
52-week low 30.4300
50-day moving average 30.5690
200-day moving average 30.7170

Share statistics

Avg vol (3-month) 3111.47k
Avg vol (10-day) 333.65k
Shares outstanding 54.31M
Implied shares outstanding 64.31M
Float 83.59M
% held by insiders 16.74%
% held by institutions 16.09%
Shares short (28 Mar 2024) 4268.9k
Short ratio (28 Mar 2024) 41
Short % of float (28 Mar 2024) 46.36%
Short % of shares outstanding (28 Mar 2024) 46.23%
Shares short (prior month 29 Feb 2024) 418.01k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 322 Jul 2019
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 317 Oct 2022

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-75.90%
Return on equity (ttm)-160.07%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -12.88M
Net income avi to common (ttm)-12.54M
Diluted EPS (ttm)-3.8400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)5.9M
Total cash per share (mrq)1.37
Total debt (mrq)289.64k
Total debt/equity (mrq)5.48%
Current ratio (mrq)5.02
Book value per share (mrq)1.34

Cash flow statement

Operating cash flow (ttm)-12.85M
Levered free cash flow (ttm)-8.99M